Daily Ards Research Analysis

Acute respiratory distress syndrome (ARDS) is a devastating complication of respiratory infections; however, the biological mechanisms that initiate its onset are poorly defined. Here we show that TNFRSF13B polymorphisms increase the risk of ARDS following SARS-CoV-2 infection up to 7.4-fold compared to the WT genotype. The increased risk was not due to immune-deficiency or impaired virus neutralization. On the contrary, TNFRSF13B mutant subjects mounted better antibody neutralization compared to subjects with WT TNFRSF13B. However, IgG from subjects expressing TNFRSF13B variants had less sialic acid, terminal galactose, and fucose than IgG from subjects with a WT genotype. Moreover, IgG from TNFRSF13B mutant subjects exhibited increased recruitment of complement factors. Thus, besides well-known actions governing plasma cell differentiation, TNFRSF13B impacts both affinity maturation and effector functions of IgG in ways that independently govern complement activation controlling inflammatory responses known to trigger ARDS.

Acute hypoxemic respiratory failure (AHRF) represents one of the most common and clinically challenging indications for invasive mechanical ventilation in the intensive care unit, characterized by profound etiological heterogeneity that demands accurate diagnosis to guide treatment. While clinical history, physical examination, and laboratory data remain essential, they are often insufficient to reliably discriminate among conditions such as acute respiratory distress syndrome (ARDS), cardiogenic pulmonary edema, and pneumonia-particularly in mechanically ventilated patients. Lung imaging has therefore emerged as an indispensable complement to clinical assessment. In this narrative review, we systematically describe the physical principles, clinical applications, and limitations of the imaging modalities currently available in critical care: chest X-ray (CXR), computed tomography (CT), lung ultrasound (LUS), electrical impedance tomography (EIT), and positron emission tomography (PET). CXR remains the most widely used bedside tool but is constrained by low sensitivity and significant interobserver variability. CT is the gold standard for morphological and quantitative lung phenotyping, enabling the assessment of recruitability, baby lung characterization, and the identification of complications, but requires patient transport and exposes patients to ionizing radiation. LUS offers real-time, bedside evaluation of aeration with high diagnostic accuracy for pneumothorax and pleural effusion, and is increasingly integrated into revised ARDS diagnostic criteria. EIT enables continuous, radiation-free monitoring of regional ventilation distribution and positive end-expiratory pressure (PEEP)-guided titration directly at the bedside. While PET provides unparalleled quantification of regional inflammation and ventilation-perfusion mismatch, it currently remains a purely investigative research tool. Finally, we discuss emerging technological and AI-driven advances-including dual-energy CT, next-generation EIT, and deep learning algorithms-that are poised to transform lung imaging from a passive diagnostic tool into an active, personalized guide to respiratory management.

Endothelial dysfunction is a key characteristic of many diseases, including atherosclerosis, hypertension, heart failure, stroke, cancer, acute respiratory distress syndrome (ARDS), peripheral vascular disease, coronavirus 2019 (COVID-19), and pulmonary arterial hypertension (PAH). To improve understanding of the roles of endothelial cells (ECs) in health and disease, EC-specific genome editing technologies have been developed in recent years. Therapeutic strategies that aim to restore a healthy endothelial monolayer include the inhibition of endothelial genes that cause EC injury and dysfunction and the induction or activation of endothelial genes that drive EC repair and regeneration. In this review, we describe established recombinase-mediated genetic modification technologies and emerging EC-specific genome editing technologies including viral and non-viral delivery of the CRISPR/Cas9 genome editing system, and we summarize the strengths and limitations of each technology. We then discuss possible avenues for future research, including the development of organ-specific EC genome editing technologies. In short, EC-specific genome editing technologies can be used to modulate gene expression selectively in ECs and even within a specific vascular bed and/or distinctive EC subtype, and, in doing so, greatly improve the understanding of vascular biology and help develop precision genetic medicine targeting the disease-causing vascular bed(s) to effectively treat diseases caused by vascular endothelial dysfunction.